



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 38/07</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/17985 (43) International Publication Date: 22 May 1997 (22.05.97)</p>
<p>(21) International Application Number: PCT/US96/18245 (22) International Filing Date: 12 November 1996 (12.11.96) (30) Priority Data: 60/006,474 13 November 1995 (13.11.95) US (71) Applicants (for all designated States except US): SMITHK-LINE BEECHAM CORPORATION [US/US]; Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). NY-COMED IMAGING AS [NO/NO]; Nycoveien 2, N-0401 Oslo (NO). (72) Inventors; and (75) Inventors/Applicants (for US only): BHATNAGAR, Pradip, Kumar [US/US]; 300 South Balderston Drive, Exton, PA 19341 (US). FISCHER, Peter, Martin [CH/NO]; Vestel- lasveien 26A, N-0382 Oslo (NO). (74) Agents: HALL, Linda, E. et al.; SmithKline Beecham Corpora- tion, Corporate Intellectual Property, UW2220, 709 Swede- land Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).</p>		<p>(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>
<p>(54) Title: HEMOREGULATORY COMPOUNDS</p>		
<p>(57) Abstract</p> <p>Novel compounds of general formula (I) which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HEMOREGULATORY COMPOUNDSField of the Invention

- 5 The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.

Background of the Invention

10

The haematopoietic system is a life-long cell renewal process whereby a defined stem cell population gives rise to a larger population of mature, differentiated blood cells (Dexter TM. Stem cells in normal growth and disease, Br Med J 1987; 195:1192-1194) of at least nine different cell lineages (erythrocytes, platelets, eosinophils, basophils, neutrophils, monocytes/macrophages, osteoclasts and lymphocytes) (Metcalf D. The Molecular Control of Blood Cells, 1988; Harvard University Press, Cambridge, MA). The stem cells are also ultimately responsible for regenerating the bone marrow following treatment with cytotoxic agents or following bone marrow transplantation.

20

The major dose-limiting toxicities of most standard anti-neoplastic drugs are related to bone marrow suppression, which if severe and prolonged, can give rise to life-threatening infectious and haemorrhagic complications. Myelosuppression is predictable and has been reported to be dose-limiting in greater than 50% of single-agent Phase I trials cytotoxic compounds (Merrouche Y, Catimel G, Clavel M. Haematopoietic growth factors and chemoprotectants; should we move toward a two-step process for phase I trials in oncology? Ann Oncol 1993; 4:471-474). The risk of infection is directly related to the degree of myelosuppression as measured by the severity and duration of neutropenia (Brody GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infections with acute leukemia. Ann In Med 1965; 64:328-334).

30

The control of haematopoiesis involves the interplay of a variety of cytokines and growth factors during various stages of the haematopoietic cascade, including early pluripotent stem cells and mature circulating effector cells. These regulatory

5 molecules include granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), and a variety of interleukines which have overlapping, additive and synergistic actions which play major roles in host defence. Mechanistically, this is accomplished by enhancing the production of granulocytes and macrophages, as

10 well as by the activation of effector cell functions (Moore MAS. Haematopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. *Cancer Surveys* 1990; 9:7-80). These co-ordinated activities support optimal host defences which are necessary for fighting bacterial, viral and fungal infections.

15 Strategies to prevent or reduce the severity of neutropenia and myelotoxicity include the use of haematopoietic growth factors and/or other haematopoietic cytokines. Such treatments are becoming common practice, in that they offer the potential of increased doses of cytotoxic agents that may improve the therapeutic efficacy if antineoplastic agents, and reduce the morbidity associated with their use (Steward

20 WP. Granulocyte and granulocyte-macrophage colony stimulating factors, *Lancet* 1993; 342:153-157). Clinical studies have demonstrated the G-, GM- and/or M-CSF may reduce the duration of neutropenia, accelerate myeloid recovery and reduce neutropenia-associated infections and other infectious complications in patients with malignancies who are receiving cytotoxic chemotherapy or in high infectious-risk

25 patients following bone marrow transplantation (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, *Lancet* 1993; 342:153-157 and Munn DH, Cheung NKV. Preclinical and clinical studies of macrophage colony-stimulating factor. *Semin Oncol* 1992; 19:395-407).

We have now found certain novel compounds which have a stimulative effect on myelopoietic cells and are useful in the treatment and prevention of viral, fungal and bacterial diseases.

5

Summary of the Invention

This invention comprises compounds, hereinafter represented as Formula (I), which have hemoregulatory activities and can be used to stimulate haematopoiesis and in
10 the prevention and treatment of bacterial, viral and fungal diseases.

These compounds are useful in the restoration of leukocytes in patients with lowered cell counts resulting from a variety of clinical situations, such as surgical induced myelosuppression, AIDS, ARDS, congenital myelodysplacis, bone marrow and organ transplants; in the protection of patients with leukopenia from infection; in the
15 treatment of severely burned patients and in the amelioration of the myelosuppression observed with some cell-cycle specific antiviral agents and in the treatment of infections in patients who have had bone marrow transplants, especially those with graft versus host disease, in the treatment of tuberculosis and in the treatment of fevers of unknown origin in humans and animals. The compounds are
20 also useful in the treatment and prevention of viral, fungal and bacterial diseases, particularly Candida, Herpes and hepatitis in both immunosuppressed and "normal" subjects.

These compounds may also be used in combination with the monomers of co-
25 pending U.S. Application No. 07/799,465 and U.S. Patent No. 4,499,081, incorporated by reference herein, to provide alternating peaks of high and low activity in the bone marrow cells, thus augmenting the natural circadian rhythm of haematopoiesis. In this way, cytostatic therapy can be given at periods of low bone marrow activity, thus reducing the risk of bone marrow damage, while regeneration
30 will be promoted by the succeeding peak of activity. This invention is also a


pharmaceutical composition, which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.

This invention further constitutes a method for stimulating the myelopoietic system of an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).

This invention also constitutes a method for preventing and treating viral, fungal and bacterial infections including sepsis, in immunosuppressed and normal animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).

Detailed Description of the Invention

The compounds of the invention are represented by structural formula (I)



wherein:

20 A_1 and A_2 independently from each other are $Z-(CH_2)_p-(NR^{11})_q$, wherein

Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two C_{1-4} alkyl, F, Cl, Br, I, C_{1-4} alkoxy, $(CH_2)_mR^{13}$, oxo, oxime, $O-C_{1-4}$ alkyloxime, hydroxy, $N(R^{12})_2$, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded;

R^1, R^2, R^3, R^4 and R^{11} independently hydrogen, C_{1-4} alkyl $C(O)R^{13}$,

C_{1-4} alkyl or R^1 , R^2 , R^3 , R^4 and R^{11} are benzyl which is optionally substituted by one or two C_{1-4} alkyl, C_{1-4} alkoxy, F, Cl, I, Br, OH, or $N(R^{12})_2$;

p is an integer from 0 to 4;


q, n and m are independently zero or one;

5


R^5 and R^6 are independently hydrogen, C_{1-4} -alkyl, C_{1-4} -alkyl-OH, C_{1-4} -alkyl-OCH₃, C_{1-4} -alkylaryl-OH, C_{1-4} -alkylaryl-OCH₃ or C_{1-4} -alkyl-COOH;

Q corresponds to structural formula (II) or (III)

10



(II)



(III)

wherein:

15

D_1 and D_2 are C_{1-8} -alkyl;

R^7 , R^8 , R^9 and R^{10} are independently hydrogen or C_{1-4} -alkyl;

R^{12} is independently hydrogen, C_1 - C_4 -alkyl or benzyl;

R^{13} is independently $-OR^{12}$, $-N(R^{12})_2$, $-SR^{12}$;

20

or a pharmaceutically acceptable salt thereof.

Z in the above Formula (I) denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,
 25 pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl,

isobenzazolyl, pyridinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl,
isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl,
pyrrolidonyl, imidazolyl, imidazolidinyl, imidazoliny, piperidyl, tetrazolyl,
5 quinuclidinyl, azetidiny, or purinyl.

Possible substituents for Z are C₁₋₄-alkyl, O-C₁₋₄-alkyl, C₁₋₄-alkyl-O-C₁₋₄-alkyl,
oxo, oxime, O-C₁₋₄-alkyloxime, hydroxy, amino, N-C₁₋₄-alkylamino,
N,N-di-C₁₋₄-alkylamino, CO, C₁₋₄-alkyl-CO and (C₁₋₄-alkyl)₂-NC(O)-.
10

R⁵ and R⁶ denote hydrogen, C₁₋₄-alkyl, C₁₋₄-alkyl-OH, C₁₋₄-alkyl-OCH₃, C₁₋₄-
alkyl-(phenyl-OH), C₁₋₄-alkyl-(phenyl-OCH₃) and C₁₋₄-alkyl-(phenyl-COOH).

Preferred compounds are those wherein Z is optionally substituted pyridinyl,
15 pyrimidinyl, pyrazinyl, pyridyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl,
azetidiny, or pyrrolidinyl.

More preferred compounds are those wherein Z is optionally substituted
2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl, 2-pyrrolidon-5-yl, 2-pyridyl, 3-pyridyl, or
20 pyrrolidinyl.

Alkyl groups may be straight or branched.

The compounds of the present invention may contain one or more asymmetric
25 carbon atoms and may exist in racemic and optically active form. All the compounds
and diastereomers are contemplated to be within the scope of the present invention.

Especially preferred compounds are:

30 ε,ε'-bis(picolinoyl-seryl)-[cyclo-(D-Lys-L-Lys)]


- ϵ,ϵ' -bis(picolinoyl-seryl)-[*cyclo*-(D-Lys-D-Lys)]
 ϵ,ϵ' -bis(picolinoyl-seryl)-[*cyclo*-(L-Lys-L-Lys)]
 ϵ,ϵ' -bis(picolinoyl)-[*cyclo*-(Lys-Lys)]
 δ,δ' -bis(picolinoyl)-[*cyclo*-(Orn-Orn)]
 5 γ,γ' -bis(picolinoyl)-[*cyclo*-(Dab-Dab)]

Methods of preparation


Compounds of formula (I) can be prepared as follows:

10

Suitable diamines of formula (IV) and (V) [definitions as in formulae (I), (II) and (III)]




15 (IV)




(V)

are reacted with two molar equivalents of an appropriate activated amino acid derivative of formula (VI), where the definitions are as in formula (I) and PG corresponds to suitable amino-protecting groups known in the art, e.g.

- 20 t-butyloxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, etc. Where the amino acid side chains R⁵ and R⁶ contain hydroxyl or carboxyl groups, these are protected in the form of ethers or esters, chosen in such a way as to permit selective removal of the amino protecting group PG without regenerating the hydroxyl or carboxyl functions. A suitable combination of protecting groups would be when PG
- 25 corresponds to benzyloxycarbonyl and the amino side chain hydroxyl or carboxyl is blocked in the form of a t-butyl ether or ester.



After removal of the protecting group PG (e.g. by hydrogenolysis in the case where PG corresponds to benzyloxycarbonyl), further acylation of the resulting diamine
 5 with two molar equivalents of an appropriately activated carboxylic acid derivative of formula (VII) is performed, followed by removal of the semi-permanent hydroxyl or carboxyl protecting groups (if present) in R⁵ and R⁶ (e.g. by acidolysis with trifluoroacetic acid in case of t-butyl ether/ester).




10

in the case where n and m in formula (I) are zero, diamines of formula (IV) and (V) are reacted directly with appropriately activated carboxylic acid derivatives of formula (VII).

15

Diketopiperazine diamines of structure (IV) can be prepared by cyclisation of the corresponding dipeptidyl precursors of structure (VIII), in which the definitions are as in formulae (I), (II) and (III). Additionally, PG in structure (VIII) stands for suitable amino-protecting groups.

20



Cyclisation through intramolecular ester aminolysis may be acid- or base-catalysed or may be induced simply by heating a solution of compounds of structure (VIII) in some inert solvent. The ester portion E in structure (VIII) may correspond e.g. to methyl, ethyl, benzyl, N-hydroxysuccinimidyl, etc. After removal of protecting groups PG, compounds of structural formula (IV) are thus obtained, which in cases where R⁷ and R⁸ are hydrogen may be converted to the imino ether compounds of structure (V) e.g. through the action of trialkyl oxonium tetrafluoroborates.

In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with pharmaceutical practice as a pharmaceutical composition.

According to a still further feature of the present invention there are provided pharmaceutical compositions comprising as active ingredient one or more compounds of Formula (I) as herein before defined or physiologically compatible salts thereof, in association with a pharmaceutical carrier or excipient. The compositions according to the invention may be presented for example, in a form suitable for oral, nasal, parenteral or rectal administration.

As used herein, the term "pharmaceutical" includes veterinary applications of the invention. These peptides may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers

may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier

5 may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies, but, preferably will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing and filling for hard gelatin capsule forms.

10 Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules. Organ specific carrier systems may also be used.

15 Alternately pharmaceutical compositions of the peptides of this invention or derivatives thereof, may be formulated as solutions of lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable

20 diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration and contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxycellulose,

25 acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.

For rectal administration, a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository. The pulverized powders may also be

30 compounded with oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.

Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propellant or provided with means for manual compression.

5

Dosage units containing the compounds of this invention preferably contain 0.05-50 mg, for example 0.05-5 mg of the compound of Formula (I) or of the salt thereof.

10 According to a still further feature of the present invention there is provided a method of stimulation of myelopoiesis which comprises administering an effective amount of a pharmaceutical composition as hereinbefore defined to a subject. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

15

The biological activity of the compounds of Formula (I) is demonstrated by the following tests.

Induction of Hematopoietic Synergistic Activity in Stromal Cells

20

The murine bone marrow derived from stromal cell line C6.4 is grown in 12 well pates in RPMI 1640 with 10% FBS. Upon reaching confluence, the C6.4 cells are washed and the media exchanged with fresh RPMI 1640 without FBS. Confluent cell layers of murine C6.4 cells are treated with compound. Cell free supernatants
25 are collected 18 hours later. Supernatants are fractionated with a Centricon-30 molecular weight cut-off membrane. C6.4 cell hematopoietic synergistic factor (HSF) activity is measured in a murine CFU-C assay.

CFU-C Assay


Bone marrow cells are obtained from C57B1/6 female mice and suspended in RPMI 1640 with 10% FBS. Bone marrow cells (7.5E+4 cells/mL) are cultured with sub
5 optimal levels of CFU plus dilutions of test C6.4 cell 30K-E supernatants from above in a standard murine soft agar CFU-C assay. Cell aggregates >50 cells are counted as colonies. The number of agar colonies counted is proportional to the amount of HSF present within the C6.4 bone marrow stromal line supernatant.

10 Effector Cell Function Assay

Female C57B1 mice are administered test compound PO daily for 8 days. Resident peritoneal exudate cells (PEC) utilized *ex vivo* from treated or untreated mice are harvested with cold calcium and magnesium-free DPBS supplemented with heparin
15 and antibiotics within 2-4 hours following the last injection. Adherent PEM populations are prepared by incubating standardized PEC suspensions in microtiter dishes for 2 hours at 37 °C (5% CO₂) and removing nonadherent cells by washing the wells with warm buffer.

20 The superoxide dismutase-inhibitable (SOD) superoxide released by effector cells in response to a *in vitro* stimulation by phorbol myristate acetate (PMA) (100-200 nM) or pre-opsonized (autologous sera) live *C. albicans* (E:T = 1:10) are quantitated in a microtiter ferricytochrome *c* reduction assay. The assay is performed in the presence of 1% gelatin/HBSS and 80 μM ferricytochrome *c* in a total volume of 200 μL/well.

25 The nmoles of cytochrome *c* reduced /well is calculated from spectrophotometric readings (550 nm) taken following a 1 hour incubation at 37 °C (5% CO₂). The amount of SOD-inhibitable cytochrome *c* reduced is determined by the inclusion of wells containing SOD (200 U/well). Baseline superoxide release is determined in the absence of stimuli. Experimental data are expressed as a percentage of the control
30 group.

ExamplesExample 1: Preparation of ϵ,ϵ' -bis(picolinoyl-seryl)-[cyclo-(D-Lys-L-Lys)]

5

a) Fmoc-D-Lys(Boc)-L-Lys(Z)-OMe

Fmoc-D-Lys(Boc)-OH (998 mg, 2.13 mmol) and NMM (0.23 mL, 2.13 mmol) were dissolved in THF (25 mL) and the solution was cooled to -15°C . $\text{Bu}^i\text{OCOC}\text{Cl}$ (0.28 mL, 2.13 mmol) was then added. After 5 min a pre-cooled solution of H-L-Lys(Z)-OMe.HCl (706 mg, 2.13 mmol) and NMM (0.23 mL) in THF (25 mL) was added. The entire mixture was stirred and was allowed to reach room temperature. After 2 h precipitated NMM.HCl was filtered off and the filtrate evaporated. The residue was redissolved in CH_2Cl_2 (70 mL), extracted successively with 5 % aq NaHCO_3 and 10 % aq citric acid (2 x 25 mL each), dried over MgSO_4 , filtered and evaporated to dryness. The title compound was obtained as a white powder (1.43 g, 90.1 %). TLC: $R_F = 0.66$ (85:10:5 $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$). FAB-MS:

15

$[\text{M} + \text{H}]^+ = 745.6$, $[(\text{M}-\text{Boc}) + \text{H}]^+ = 645.4$; $\text{C}_{41}\text{H}_{52}\text{N}_4\text{O}_9$ requires 744.88.

20

b) cyclo-[D-Lys(Boc)-L-Lys(Z)]

Fmoc-D-Lys(Boc)-L-Lys(Z)-OMe (1.0 g, 1.34 mmol) was dissolved in 50 % $\text{Et}_2\text{NH}/\text{CH}_2\text{Cl}_2$ (50 mL) and the mixture was stirred during 2 d. The resulting suspension was evaporated, co-evaporated several times with PhMe and taken to dryness under high vacuum. The residue of H-D-Lys(Boc)-L-Lys(Z)-OMe (TLC:

25

$R_f = 0.16$, 85:10:5 $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$) was resuspended in EtOAc (50 mL) and heated under reflux for 18 h. After this time the conversion to the diketopiperazine was complete as evidenced by TLC ($R_f = 0.58$ only). The cooled solution was evaporated to dryness. The residue was triturated with 10 % aq citric acid (50 mL),
5 filtered and washed on the sinter with H_2O . After drying, the crude product was ground in Et_2O , filtered and dried to afford the pure title compound (406 mg, 61.7 %). FAB-MS: $[\text{M} + \text{H}]^+ = 491.4$, $[(\text{M}-\text{Boc}) + \text{H}]^+ = 391.3$; $\text{C}_{25}\text{H}_{38}\text{N}_4\text{O}_6$ requires 490.60.

10 c) ϵ,ϵ' -bis(picolinoyl-seryl)-[*cyclo*-(D-Lys-L-Lys)]

cyclo-[D-Lys(Boc)-L-Lys(Z)] (100 mg, 0.2 mmol) was dissolved in 1 M Me_3SiBr , 1 M PhSMe in CF_3COOH (20 mL) with ice-bath cooling. The mixture was stirred under N_2 and with cooling for 45 min. The cooling bath was then
15 removed and stirring was continued for 30 min. H_2O (0.3 mL) was added and the mixture was evaporated. The residue was triturated with Et_2O and the precipitated product was collected by centrifugation. It was washed twice more with Et_2O and dried.


The resulting *cyclo*-[D-Lys-L-Lys] was suspended in DMF (25 mL) and
20 added to a pre-activated (5 min) solution of Z-Ser(Bu^t)-OH (153 mg, 0.4 mmol), PyBOP (208 mg, 0.4 mmol), HOBt (54 mg, 0.4 mmol) and NMM (0.13 mL, 1.2 mmol) in DMF (5 mL). The mixture was stirred for 2 h. The resulting clear solution was evaporated and treated with 5 % aq NaHCO_3 . The precipitated oil was extracted into CH_2Cl_2 . The extract was washed successively with 10 % aq citric
25 acid and 2 M aq NaCl. The organic layer was dried over MgSO_4 , filtered and evaporated. The intermediate ϵ,ϵ' -bis[Z-Ser(Bu^t)]-[*cyclo*-(D-Lys-L-Lys)] was obtained as a discoloured oil. TLC: $R_f = 0.62$ (85:10:5 $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$) and was used directly in the next reaction step.

ϵ,ϵ' -bis[Z-Ser(Bu^t)]-[*cyclo*-(D-Lys-L-Lys)] was redissolved in MeOH (50 mL) and was hydrogenolysed with 10 % Pd(C) catalyst (50 mg) for 90 min. The catalyst was then removed by filtration and the filtrate was evaporated. The oily residue was redissolved in DMF and added to a pre-activated (with PyBOP, HOBT and NMM as above; 5 min) solution of picolinic acid (49 mg, 0.4 mmol) in DMF (15 mL). After overnight reaction DMF was removed under vacuum. The residue was worked up as the previous intermediate except that no extraction with aqueous citric acid was performed. The intermediate ϵ,ϵ' -bis[picolinyl-Ser(Bu^t)]-[*cyclo*-(D-Lys-L-Lys)] (discoloured oil, TLC R_F = 0.56) was redissolved in 2 % aq CF₃COOH (25 mL) and the solution was stirred for 90 min. It was then evaporated and the residue was treated with Et₂O. The precipitated material was collected by centrifugation and drying to afford the crude title compound (16 mg, 12.0 %). This was dissolved in 4 mL 0.1 % aq CF₃COOH and chromatographed on a RP-HPLC column (Vydac 218TP1022) at 9 mL/min using a gradient from 20 to 40 % MeCN in 0.1 % aq CF₃COOH over 60 min. The eluant was monitored at 230 nm; appropriate peak fractions were collected, pooled and lyophilised to provide the pure title compound (3.0 mg). Anal. RP-HPLC: t_R = 15.7 min, purity > 98 % (Vydac 218TP54, 1 mL/min, 20 to 50 % MeCN in 0.1 % aq CF₃COOH over 20 min, λ = 215 nm). FAB-MS: [M + H]⁺ = 641.3, [M + Na]⁺ = 663.2; C₃₀H₄₀N₈O₈ requires 640.69.

We claim:

1. Compounds having hemoregulatory activity of the formula

5





wherein:

- 10 A_1 and A_2 independently from each other are $Z-(CH_2)_p-(NR^{11})_q$, wherein
 Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two C_{1-4} alkyl, F, Cl, Br, I, C_{1-4} alkoxy, $(CH_2)_mR^{13}$, oxo, oxime, $O-C_{1-4}$ alkyloxime, hydroxy, $N(R^{12})_2$, acylamino or aminoacyl
 15 groups, 8, 9, 10 membered monocyclic ring systems being excluded;

- R^1, R^2, R^3, R^4 and R^{11} independently hydrogen, C_{1-4} alkyl $C(O)R^{13}$,
 C_{1-4} alkyl or R^1, R^2, R^3, R^4 and R^{11} are benzyl which is optionally substituted by
 one or two C_{1-4} alkyl, C_{1-4} alkoxy, F, Cl, I, Br, OH, or $N(R^{12})_2$;
 20 p is an integer from 0 to 4;
 q, n and m are independently zero or one;

- R^5 and R^6 are independently hydrogen, C_{1-4} -alkyl, C_{1-4} -alkyl-OH,
 C_{1-4} -alkyl-OCH₃, C_{1-4} -alkylaryl-OH, C_{1-4} -alkylaryl-OCH₃ or C_{1-4} -alkyl-COOH;
 25

Q corresponds to structural formula (II) or (III)



5 wherein:

D_1 and D_2 are C_{1-8} -alkyl;

R^7 , R^8 , R^9 and R^{10} are independently hydrogen or C_{1-4} -alkyl;

R^{12} is independently hydrogen, C_1 - C_4 -alkyl or benzyl;

R^{13} is independently $-OR^{12}$, $-N(R^{12})_2$, $-SR^{12}$;

10

or a pharmaceutically acceptable salt thereof.

2. Compounds according to claim 1, wherein Z denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazoliny, piperidyl, tetrazolyl, quinuclidinyl, azetidiny, or purinyl.

3. Compounds according to claim 2, wherein Z denotes an optionally substituted 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl, 2-pyrrolidon-5-yl, 2-pyridyl, 3-pyridyl, or pyrrolidinyl.

4. Compounds according to claim 1, wherein Z is optionally mono-, poly- or mixed substituted by C₁₋₄-alkyl, O-C₁₋₄-alkyl, C₁₋₄-alkyl-O-C₁₋₄-alkyl, oxo, oxime, O-C₁₋₄-alkyloxime, hydroxy, amino, N-C₁₋₄-alkylamino, N,N-di-C₁₋₄-alkylamino, CO, C₁₋₄-alkyl-CO or (C₁₋₄-alkyl)₂-NC(O)-.

5

5. Compounds according to any one of claims 1 to 3 wherein Z is optionally mono-, poly- or mixed substituted by methyl, ethyl, methoxy, methoxymethyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.

10

6. Compounds according to any one of claims 1 to 5 wherein R¹, R², R³, R⁴ and R¹¹ independently from each other denote hydrogen, methyl, ethyl, propyl, butyl, C₁₋₄-alkylcarboxylic acid or C₂₋₄-alkylhydroxy.

15

7. Compounds according to any one of claims 1 to 6 wherein R⁵ and R⁶ denote hydrogen, C₁₋₄-alkyl, C₁₋₄-alkyl-OH, C₁₋₄-alkyl-OCH₃, C₁₋₄-alkyl-(phenyl-OH), C₁₋₄-alkyl-(phenyl-OCH₃) or C₁₋₄-alkyl-(phenyl-COOH).

20

8. Compounds according to any one of claims 1 to 7 wherein R⁷, R⁸, R⁹ and R¹⁰ are independently hydrogen, methyl, ethyl, propyl or butyl.

9. A compound of Claim 1 which is chosen from the group consisting of:

ε,ε'-bis(picolinoyl-seryl)-[*cyclo*-(D-Lys-L-Lys)];

ε,ε'-bis(picolinoyl-seryl)-[*cyclo*-(D-Lys-D-Lys)];

25

ε,ε'-bis(picolinoyl-seryl)-[*cyclo*-(L-Lys-L-Lys)];

ε,ε'-bis(picolinoyl)-[*cyclo*-(Lys-Lys)];

δ,δ'-bis(picolinoyl)-[*cyclo*-(Orn-Orn)]; or

γ,γ'-bis(picolinoyl)-[*cyclo*-(Dab-Dab)].

10. Process for producing a compound as claimed in any one of claims 1 to 8, said process comprising
- a) cyclising a suitably protected dipeptide through intramolecular ester amminolysis;
 - 5 b) optionally converting the resulting diketopiperazine into the imminoether compound;
 - c) optionally reacting one equivalent of the resulting, suitably protected diamine with two equivalents of appropriate, suitably protected amino acids;
 - d) optionally removing the amino acid protecting groups
 - 10 e) acylating the resulting diamine with heterocyclic acids.
 - f) optionally reducing and/or oxidizing any functional groups and/or removing any remaining protecting groups, and
 - g) optionally forming a pharmaceutically acceptable salt thereof.
- 15 11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier.
12. A method of stimulating the myelopoietic system which comprises administering to a subject in need thereof, an effective amount to stimulate said
20 myelopoietic system of a compound to any one of claims 1 to 8.
13. A method of preventing or treating viral, fungal and bacterial infections which comprises administering to a subject in need thereof, an effective amount of a compound of any one of claims 1 to 8.
- 25 14. A method of preventing or treating sepsis which comprises administering to a subject in need thereof, an effective amount of a compound of any one of claims 1 to 8.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/18245

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/07

US CL :530/330

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/330; 514/18

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,499,081 (LAERUM) 12 February 1985, see entire document.	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

06 FEBRUARY 1997

Date of mailing of the international search report

04 MAR 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID LUKTON

Telephone No. (703) 308-0196